<DOC>
	<DOCNO>NCT00916123</DOCNO>
	<brief_summary>The purpose study test effectiveness experimental drug , 177Lu-J591 antibody combination docetaxel chemotherapy metastatic , castrate-resistant prostate cancer .</brief_summary>
	<brief_title>Docetaxel/Prednisone Plus Fractionated 177Lu- J591 Antibody Metastatic , Castrate-resistant Prostate Cancer</brief_title>
	<detailed_description>This research do standard treatment metastatic prostate cancer grow despite medical surgical therapy curative . Existing treatment , docetaxel use part study , may work temporarily , unfortunately cancer continue grow . This test drug , 177Lu-J591 , design seek prostate cancer cell deliver lethal dose radiation area cancer , normal area . Some normal organ ( liver , kidney bone marrow ) receive radiation dose within acceptable limit .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Histologic diagnosis prostate adenocarcinoma . Patient must progressive metastatic prostate cancer despite adequate medical surgical castration therapy . Serum testosterone &lt; 50 mg/ml . Patients previously receive docetaxel must meet BOTH follow criterion : reason docetaxel discontinuation must NOT progression disease receive drug ( i.e . progression cancer must AFTER docetaxel discontinuation ) AND All docetaxelrelated toxicity must resolve &lt; grade 1 ( exception alopecia ) pt must eligible criterion Use red blood cell platelet transfusion within 4 week treatment . Use hematopoietic growth factor within 4 week treatment.Prior cytotoxic chemotherapy and/or radiation therapy within 4 week treatment . Bone scan demonstrate confluent lesion involve axial appendicular skeleton ( `` superscan '' ) . Prior radiation therapy encompass &gt; 25 % skeleton.Prior treatment 89Strontium 153Samarium contain compound ( e.g . Metastron® , Quadramet® ) . Platelet count &lt; 150,000/mm3 . Absolute neutrophil count ( ANC ) &lt; 2,000/mm3 . Hematocrit &lt; 30 percent Hemoglobin &lt; 10 g/dL . Abnormal coagulation profile ( PT INR , PTT ) &gt; 1.3 x upper limit normal ( unless therapeutic anticoagulation ) . Serum creatinine &gt; 2.5 mg/dL . AST ( SGOT ) &gt; 2.5x ULN . Bilirubin ( total ) &gt; 1.5x ULN . Serum calcium &gt; 11 mg/dL . Active serious infection . Active angina pectoris New York Heart Association Class IIIIV . ECOG Performance Status &gt; 2 . Life expectancy &lt; 6 month . Deep vein thrombosis and/or pulmonary embolus within 1 month study entry . Other serious illness ( e ) might preclude completion study interfere determination causality adverse effect experience study . Prior antiPSMA monoclonal antibody therapy exception ProstaScint® . Prior investigational therapy within 6 week treatment . Known history HIV . Known history myelodysplastic syndrome leukemia</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>castrate-resistant prostate cancer</keyword>
	<keyword>CRPC</keyword>
</DOC>